Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$67.54 +0.7%	$73.10	$61.24 ▼ $87.68	$209.47B	0.49	5.22 million shs	3.80 million shs
MNPR Monopar Therapeutics	$39.59 +4.1%	$36.21	$1.72 ▼ $54.30	$242.01M	1.01	356,130 shs	11,576 shs
MSTR Strategy	$317.20 +1.8%	$294.68	$101.00 ▼ $543.00	$81.63B	3.46	17.97 million shs	13.47 million shs
SEZL Sezzle	$44.80 +4.8%	$41.73	$6.73 ▼ $79.59	$1.52B	8.73	734,120 shs	773,566 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	-1.21%	+0.43%	-13.34%	+0.21%	-1.78%
MNPR Monopar Therapeutics	-0.89%	+16.55%	+11.07%	+24.74%	+944.51%
MSTR Strategy	+0.30%	+4.99%	+5.91%	-15.01%	+148.53%
SEZL Sezzle	+0.66%	+12.03%	+9.12%	-2.31%	+326.05%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZN AstraZeneca	3.361 of 5 stars	3.5	5.0	1.7	0.0	2.6	0.0	1.3
MNPR Monopar Therapeutics	2.3231 of 5 stars	3.4	3.0	0.0	0.0	2.7	2.5	0.0
MSTR Strategy	4.1371 of 5 stars	4.5	2.0	0.0	4.1	2.0	2.5	0.0
SEZL Sezzle	3.4956 of 5 stars	3.7	2.0	0.0	0.0	2.2	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	3.09	Buy	$86.80	28.51% Upside
MNPR Monopar Therapeutics	2.75	Moderate Buy	$55.33	39.77% Upside
MSTR Strategy	2.91	Moderate Buy	$508.09	60.18% Upside
SEZL Sezzle	3.33	Buy	$61.42	37.09% Upside

Current Analyst Ratings Breakdown

Latest MNPR, MSTR, AZN, and SEZL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/15/2025	AZN AstraZeneca	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
4/2/2025	MNPR Monopar Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/1/2025	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/1/2025	MSTR Strategy	Monness Crespi & Hardt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$220.00
3/19/2025	MNPR Monopar Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$76.00
3/19/2025	MSTR Strategy	Monness Crespi & Hardt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral
2/26/2025	SEZL Sezzle	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$62.00 ➝ $62.83
2/13/2025	AZN AstraZeneca	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy
2/12/2025	AZN AstraZeneca	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
2/10/2025	MSTR Strategy	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$515.00 ➝ $421.00
2/7/2025	MSTR Strategy	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$560.00

(Data available from 4/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	3.87	$5.73 per share	11.79	$13.18 per share	5.12
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$1.88 per share	N/A
MSTR Strategy	$463.46M	176.14	N/A	N/A	$76.07 per share	4.17
SEZL Sezzle	$271.13M	5.59	$0.22 per share	202.22	$3.88 per share	11.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.26	29.89	13.51	1.42	13.01%	32.23%	12.31%	4/29/2025 (Estimated)
MNPR Monopar Therapeutics	-$8.40M	-$3.60	N/A	N/A	N/A	N/A	-107.21%	-87.57%	5/8/2025 (Estimated)
MSTR Strategy	-$1.17B	-$5.63	N/A	∞	N/A	-251.73%	-19.01%	-10.88%	5/1/2025 (Estimated)
SEZL Sezzle	$7.10M	$2.18	4.77	3.55	N/A	25.29%	101.18%	18.90%	5/6/2025 (Estimated)

Latest MNPR, MSTR, AZN, and SEZL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SEZL Sezzle	$0.32	N/A	N/A	N/A	$64.75 million	N/A
5/8/2025	N/A	MNPR Monopar Therapeutics	-$0.65	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	MSTR Strategy	-$0.0233	N/A	N/A	N/A	$116.66 million	N/A
4/29/2025	Q1 2025	AZN AstraZeneca	$1.10	N/A	N/A	N/A	$13.71 billion	N/A
3/31/2025	Q4 2024	MNPR Monopar Therapeutics	-$0.36	-$2.23	-$1.87	-$2.23	N/A	N/A
2/25/2025	Q4 2024	SEZL Sezzle	$0.5133	$0.7317	+$0.2183	$4.21	$73.90 million	$271.13 billion
2/6/2025	Q4 2024	AZN AstraZeneca	$1.10	$1.05	-$0.05	$0.48	$14.19 billion	N/A
2/5/2025	Q4 2024	MSTR Strategy	-$0.13	-$3.20	-$3.07	-$3.03	$122.73 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$2.06	3.05%	+1.98%	91.15%	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
MSTR Strategy	N/A	N/A	N/A	N/A	N/A
SEZL Sezzle	N/A	N/A	N/A	N/A	N/A

Latest MNPR, MSTR, AZN, and SEZL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/6/2025	AZN AstraZeneca	semi-annual	$1.03	2%	2/21/2025	2/21/2025	3/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.65	0.93	0.74
MNPR Monopar Therapeutics	N/A	5.41	5.41
MSTR Strategy	0.39	0.71	0.65
SEZL Sezzle	1.54	2.40	2.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
MNPR Monopar Therapeutics	1.83%
MSTR Strategy	59.84%
SEZL Sezzle	2.02%

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
MNPR Monopar Therapeutics	34.90%
MSTR Strategy	9.16%
SEZL Sezzle	57.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	83,500	3.10 billion	N/A	Optionable
MNPR Monopar Therapeutics	10	6.11 million	3.97 million	Not Optionable
MSTR Strategy	2,150	257.35 million	217.70 million	Optionable
SEZL Sezzle	540	33.85 million	2.38 million	Not Optionable

MNPR, MSTR, AZN, and SEZL Headlines

Recent News About These Companies

Sezzle (NASDAQ:SEZL) Trading 5.7% Higher - Here's Why

April 17 at 1:46 PM | marketbeat.com

Portolan Capital Management LLC Acquires New Position in Sezzle Inc. (NASDAQ:SEZL)

April 17 at 6:25 AM | marketbeat.com

Sezzle Inc. (NASDAQ:SEZL) Short Interest Up 413.6% in March

April 16 at 6:37 PM | marketbeat.com

Sezzle (NASDAQ:SEZL) Shares Gap Up - Should You Buy?

April 16 at 10:46 AM | marketbeat.com

Sezzle to Announce First Quarter 2025 Results and Participate in Upcoming Investor Conferences

April 14 at 3:50 PM | globenewswire.com

Sezzle (NASDAQ:SEZL) Stock Price Up 4.9% - Time to Buy?

April 10, 2025 | marketbeat.com

Sezzle (NASDAQ:SEZL) Shares Gap Down - Time to Sell?

April 6, 2025 | marketbeat.com

5,500 Shares in Sezzle Inc. (NASDAQ:SEZL) Bought by Swiss National Bank

March 30, 2025 | marketbeat.com

Sezzle (NASDAQ:SEZL) Trading Down 5.6% - What's Next?

March 27, 2025 | marketbeat.com

Jim Cramer on Sezzle (SEZL): ‘Too Many Players – This One’s a No!’

March 25, 2025 | insidermonkey.com

Bank of New York Mellon Corp Purchases 1,378 Shares of Sezzle Inc. (NASDAQ:SEZL)

March 23, 2025 | marketbeat.com

Sezzle (NASDAQ:SEZL) Trading 6.8% Higher - Here's What Happened

March 20, 2025 | marketbeat.com

Is Sezzle Inc. (SEZL) the Best Multibagger Stock to Buy in 2025?

March 13, 2025 | insidermonkey.com

Visa Strengthens Fraud Prevention With New Scam Disruption Initiative

March 12, 2025 | msn.com

Sezzle Redefines the Shopping Experience with New Features for Smarter Spending

March 12, 2025 | globenewswire.com

Sezzle Announces Six-for-One Stock Split and $50 Million Stock Repurchase Program

March 10, 2025 | globenewswire.com

Sezzle Inc. Reports Strong 2024 Earnings Call

February 27, 2025 | tipranks.com

Sezzle Inc. Reports Strong 2024 Financial Growth

February 25, 2025 | tipranks.com

Sezzle Inc. (SEZL) Q4 2024 Earnings Call Transcript

February 25, 2025 | seekingalpha.com

Sezzle Inc. 2024 Q4 - Results - Earnings Call Presentation

February 25, 2025 | seekingalpha.com

Sezzle Inc. (SEZL) Surpasses Q4 Earnings and Revenue Estimates

February 25, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
3 Defense Stocks Set to Benefit From Increased Military Spending
By Chris Markoch | March 20, 2025
View 3 Defense Stocks Set to Benefit From Increased Military Spending
MicroStrategy Sees Insider Buy-Sell Action in Q1
By Thomas Hughes | April 7, 2025
View MicroStrategy Sees Insider Buy-Sell Action in Q1
Strategy’s $5 Million Bitcoin Target: Beacon or Bagholder?
By Jea Yu | April 9, 2025
View Strategy’s $5 Million Bitcoin Target: Beacon or Bagholder?

MNPR, MSTR, AZN, and SEZL Company Descriptions

AstraZeneca NASDAQ:AZN

$67.54 +0.49 (+0.74%)

Closing price 03:59 PM Eastern

Extended Trading

$67.66 +0.11 (+0.17%)

As of 05:59 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Monopar Therapeutics NASDAQ:MNPR

$39.59 +1.57 (+4.13%)

Closing price 04:00 PM Eastern

Extended Trading

$38.88 -0.71 (-1.78%)

As of 04:05 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Strategy NASDAQ:MSTR

$317.20 +5.54 (+1.78%)

Closing price 04:00 PM Eastern

Extended Trading

$317.33 +0.13 (+0.04%)

As of 06:01 PM Eastern

Strategy Incorporated, formerly known as MicroStrategy, provides artificial intelligence-powered enterprise analytics software and services in the United States, Europe, the Middle East, Africa, and internationally. It offers Strategy ONE, a platform that allows non-technical users to access novel and actionable insights for decision-making, and Strategy Cloud for Government, which provides always-on threat monitoring designed to meet the strict technical and regulatory standards of governments and financial institutions. The company also delivers Strategy Support, helping customers achieve system availability and usage goals through responsive troubleshooting; Strategy Consulting, offering architecture and implementation services; and Strategy Education, which includes free and paid learning options. In addition, the company is actively involved in Bitcoin development. The company offers its services through direct sales force and channel partners. It serves the U.S. government, state and local governments, and government agencies, as well as a range of industries, including retail, banking, technology, manufacturing, insurance, consulting, healthcare, telecommunications, and the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

Sezzle NASDAQ:SEZL

$44.80 +2.06 (+4.82%)

Closing price 04:00 PM Eastern

Extended Trading

$45.17 +0.37 (+0.83%)

As of 05:49 PM Eastern

Sezzle Inc. operates as a technology-enabled payments company primarily in the United States and Canada. The company provides payment solution in-store and at online retail stores; and through proprietary payments solution that connects consumers with merchants. It also offers Sezzle Platform that provides a payments solution for consumers that extends credit at the point-of-sale allowing consumers to purchase and receive the ordered merchandise at the time of sale while paying in installments over time; Pay-in-Four, which allows consumers to pay a fourth of the purchase price up front and then another fourth of the purchase price every two weeks thereafter over a total of six weeks; Pay-in-Full that allows consumers to pay for the full value of their order up-front through the Sezzle Platform without the extension of credit; and Pay-in-Two and other alternative installment options, which allow consumer to pay half of the value of their order up-front and the second half in two weeks. In addition, the company provides Sezzle Virtual Card that allows consumers to access the Sezzle Platform in the form of close-end installment loans and shop with merchants that are not integrated with Sezzle; Sezzle Anywhere, a paid subscription service that allows consumers to use their Sezzle Virtual Card at any merchant online or in-store; Sezzle Premium, a paid subscription service that allows its consumers to access large, non-integrated premium merchants; and Sezzle Up, an opt-in feature of the Sezzle Platform. Further, it offers Long-Term Lending through collaboration with third-party lenders and Product Innovation. Sezzle Inc. was incorporated in 2016 and is headquartered in Minneapolis, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time